- This event has passed.
CONSULTATION ON THE CHALLENGES FACED BY THE INDIAN GENERIC INDUSTRYOrganised by ISID & TWN19 March 2020
March 19 @ 09:30 - 16:30 UTC+5.5
Indian pharmaceutical industry’s position as a global player is widely acknowledged and is one of the most successful industries in India. It is an important contributor of India’s growing economy. Indian pharmaceutical market continues to play a pivotal role in manufacturing critical, high‐quality and lowcost medicines not only for the domestic markets but also for global markets. World‐class capabilities and favourable market conditions over the last many years have ensured that India continues to be one of the most rewarding pharmaceutical markets in the world.
However, in the current decade, Indian generic pharmaceutical industry has been facing some formidable challenges which have impacted its growth trajectory. These include impact of the product patent regime, increased competition, heavy dependence on API imports from China, reduced values from new product launches and disruptions from evolving regulatory landscapes.
The enactment of TRIPS Agreement has truly altered the business of the pharmaceutical industry. There have been concerns over Indian generic companies’ use of the WTO-TRIPS platform especially with regard to flexibilities that favour the growth of the indigenous industry. The generic industry has been reluctant in exploiting the ingrained flexibilities such as oppositions and compulsory licenses to disallow monopolies on life saving drugs and bring new drugs into the market. There have been voices over patents and its effects on India’s public healthcare and access to affordable medicines and call for effective and timely interventions.
How do Indian pharmaceutical companies refine their strategy and re‐orient their business model to embrace these challenges? As the government of India is embarking on building a new Industrial Policy aimed at promoting industrial growth and reducing the regulatory hurdles, it offers us a timely opportunity to drive‐out inefficiencies and build new‐age capabilities.
In this background, Institute for Studies in Industrial Development (ISID) and The Third World Network (TWN) are organizing a consultation to expand the understanding on the issues being faced by the Indian generic manufacturers. It looks forward to elicit pragmatic responses on issues being faced by generic manufacturers, which will help in understanding the areas where support from the government and regulatory agencies need to provide to bring the industry back on the growth trajectory of the past. Such a discussion on pro-generic policy design will further enable the formulation of recommendations for possible policy suggestions for access to medicines.
Click here to download the Overview and Schedule of the Consultation